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I NAL I PIP I NOR 1 CIP I PEF I TRO I CLI 
S MIC, 8 2 0.03 0.015 0.125 0.25 0.015 
MIC. 16 4 0.125 0.015 0.25 0.25 0.015 
Conclusions: CIP susceptibility of Pm has continuously 
decreased during this decade. Cross-resistance to quinolones in CIP- 
resistant Pm was noted. Against Pm, CLI was the most active of the 
quinolones tested. 
Tolerability/toxicity 
Ip2371 Ciprofloxacin inhibits experimental fracture 
healing 
P.M. Huddleston, M.S. Rouse, K.E. Piper, A.D. Hanssen, R. Patel, 
J.M. Steckelberg. Mayo Clinic, Rochester, MN, U S A  
Previous studies of quinolones have demonstrated chondrotoxicity to 
developing articular cartilage in juvenile mammals. Fracture repair 
involves cartilage formation followed by differentiation into cancel- 
lous bone, an analogous situation to developing articular cartilage. We 
compared the healing of experimental fractures in rats after 
ciprofloxacin exposure versus no ciprofloxacin exposure. 40 male 
Wistar rats were divided equally to receive either ciprofloxacin (50 
mg/kg) b.i.d. or no treatment for 21 days beginning 7 days after 
production of experimental bilateral non-displaced implant-stabilized 
femur fractures. Four weeks post-fracture, the animals were sacrificed 
and femurs harvested for mechanical strength testing, and radiologi- 
caand histologic examination. 
N 30min Toque Torsional Rigidity 
Ser Conc Mean Nmm fS.E. Mean Nmm / deg S E .  
NoTreatment 20 -- 338 f 17 39 fo.9 
Cipmfloxacin 20 5.4 284 f8 20 f 1.1 
Torque and torsional rigidity testing results were analyzed by rank 
sum analysis. Radiographic analysis revealed a decreased amount of 
bridging callus and delayed healing in the ciprofloxacin-exposed 
group. Microscopically, the ciprofloxacin-exposed fractures 
contained decreased cartilage cellularity, fibrous proliferation, and 
matrix degeneration. Ultrastructural changes included decreased 
collagen production, and cell membrane disruption. The torsional 
rigidity of experimental fracture callus was significantly (p<0.05) less 
after ciprofloxacin exposure early in the fracture repair process than 
after no treatment. 
lp2381 A new method for testing the chondrotoxicity 
of ciprofloxacin 
G. Seiberl, M. Egerbacher, I. Waiter, B. Wolfesberger. Departmertt 
o j  Infectious Diseases, KFJ-Hospital, If’ienna Institute ~$Histologx 
University oj I gterinary Medicine, I’ienna, Austria 
Objectives: Ciprofloxacin, a frequently used fluoroquinolone, is 
wpposed to be chondrotoxic in juvenile humans, since animal stud- 
ies have shown damage of articular cartilage in weight-bearing joints. 
Mg-free diet leads to similar lesions. It is speculated that quinolone- 
induced arthropathy is due to chelation of magnesium. This divalent 
cation is important for regular function of integrins, a group of trans- 
membrane proteins which connect extracellular matrix proteins with 
the cytoskeleton. 
Methods: We cultivated rat and human chondrocytes in CFX- 
supplemented and Mg-free medium in order to test in vivo findings 
and to elucidate the possible role of integrins in this drug’s side effects. 
In addition, we performed attachment assays to test the ability of 
chondrocytes to adhere to collagen type I1 in the presence of 
ciprofloxacin and in an Mg-free environment. 
Results: Chondrocytes cultivated in CFX-supplemented medium 
(160 I/mL) or Mg-free medium showed decreased ability to adhere 
to growth support, cell shape changes, alterations in actin and 
vimentin cytoskeleton, and reduced proliferation rate (3% compared 
to 81% in control culture). Attachment of chondrocytes to collagen 
type 11-coated cover slips was reduced by 20% in the CFX group 
and 55% in the Mg-free group on day 1. This effect even increased 
after 4 days of culture in the respective medium (by 80% in the CFX 
and Mg-Gee group). 
Conclusions: Mg deficiency might exert its action via integrins, 
resulting in decreased ability to attach to extracellular matrix proteins 
and cytoskeletal changes. This is a possible explanation of cartilage 
lesions found in vivo. Our attachment assay proves to be an easy-to- 
use experimental set-up to test ciprofloxacin and other quinolones 
for their chondrotoxic effects. 
Effects of ciprofloxacin on cartilage in juvenile 
beagles 
R. Stahfmann, S. Kiihner, M. Shakibaei, R. Schwabe, D. Van 
Sickle. Freie Uniuersitiit Berlin, Institutfiir Toxikologie, Berlin, Germany 
We studied the effects of ciprofloxacin in immature Beagles. 1C-11- 
week-old dogs were dosed orally for 5 days with 0 (n=3), 30 ( n = 5 ) ,  
or 200 ( n = 5 )  mg ciprofloxacin/kg body weight. Plasma concentra- 
tions were measured by HPLC 1 h after dosing. In view of the high 
doses used, the plasma concentrations were rather low. For example, 
peak concentrations in the high-dose group were 6.6k0.9 mg/L (day 
l ) ,  3.9k1.4 mg/L (day 3) ,  and 2.6k1.6 mg/L (day 5). In control 
dogs and in dogs treated with the low dose of ciprofloxacin, no 
pathologic changes were seen by light microscopy. However, cleft 
formation and erosions were observed in joint cartilage from 2 of 5 
dogs treated with 200 mg/kg. Using antibodies against a B1-integrin, 
fibronectin and collagen type 11, the effects were studied by immuno- 
histochemistry. The most sensitive alteration was an increase in 
fibronectin, which was detectable in the vicinity of the lesions in 
cartilage samples from the high-dose group dogs. Electron 
microscopy revealed alterations in chondrocytes from dogs treated 
with ciprofloxacin, e.g. swollen mitochondria and enlarged endo- 
plasmic reticulum. 
Data are part of the doctoral thesis of Susanne Kiihner to be 
submitted to the Fachbereich Humanmedizin, Freie Universitat 
Berlin. 
Supported by a grant from BAYER AG, Wuppertal, Germany. 
P240 I Quinolone-induced chondrotoxicity in 
immature rats can be reduced by magnesium 
and tocopherol 
R. Stahlmann, E. Lozo, K. Pfister, R. Schwabe, M. Shakibaei, J. 
Vormann. Freie Universitd Berlin, Institurfur Toxikologie, Berlin, 
Germany 
Quinolones induce joint cartilage lesions in immature animals; iden- 
tical joint cartilage lesions can be induced by feeding a magnesium- 
deficient diet. We now tried to find out whether cartilage lesions can 
be diminished if quinolone-treated immature rats (31 days old) are 
supplemented with additional magnesium. To avoid pharmacokinetic 
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interactions, aninials were treated by different routes of application 
with the quinolone or the magnesium ((A) 2x600 mg ofloxacin/kg 
P O  plus MgClr solution SC; (B) 2X 600 mg ciprofloxacin/kg SC plus 
magnesium/tocopherol-suppleniented diet). With both experiinen- 
tal approaches the number of lesions were significantly reduced in the 
magnesium-supplemented groups. For example, in knee joints from 
ciprofloxacin-treated juvenile rats ( ) I =  12) we found 16 lesions in 
animalt with normal diet but only 7 lesions (-56%) in the rats with 
a niagnesium/tocopherol-enriched diet. Our data further support the 
role of a (latent) magnesium deficiency in the pathogenesis of 
quinolone-induced arthropathy in rats. 
Data are part of the doctoral theses of E. Lozo and K. Pfister to 
be submitted to the Fachbereich Humanmedizin, FU Berlin. 
Supported by a grant from DFG. 
ml Chondrotoxicity and kinetics of ofloxacin in 
juvenile rats after multiple doses 
K. Schwabe, E. Lozo, I .  Bauniann-Wilschke, K. Stahlniann. Freie 
L'iiiucrsitaf Berlin, Kliii. Phrmako lu~ie  G Toxikul., Brrlin, Germariy 
Quinolonea are chondrotoxic, but studiet correlating target tissue 
kinetics with the pathologic findings under clinically relevant condi- 
tions arc lacking. We treated juvenile Wistar rats with oral doses of 
ofloxaciii (0, 30 and 100 mg/kg; 2xdaily for 5 days plus one dose 
on day 6) and measured concentrations in plasma, joint cartilage and 
bone at 45, 90, 180 and 360 niin after dosing (n=6 per group). 
Pharniacokinetic variables were calculated using the TOPFIT 
program. Additional groups of innnature rats were treated corre- 
spondingly and their knee joint cartilage was evaluated histologically. 
Lesions were seen in 2 of 5 rats in the high-dose group only. The 
mean peak plasma concentrations (k SD) in the high-dose group 
were 10.9?5.7, 13.9k6.5 and 8.022.5 nig/L on days 1, 3 and 6 of 
the treatment period (45 or 90 min after dosing). Mean concentra- 
tions in cartilage were 2.5-3.5 tiines higher. Pharniacokinetic vari- 
ables in plasma (and cartilage) on days 1, 3 and 6 of treatment were 
calculated as follows: (a) elimination half-life: 116 (162), 153 (184) 
and 197 (196) min; (b) AUC: 2393 (11188), 2884 (9676) and 2230 
(9174) mg/LXniin. Concentrations in bone were in the similar range 
as the concentrations in cartilage. Our data show that cartilage lesions 
can be induced by using doses which lead to plasma concentrations 
in rats that are approximately 2-3 times higher than during ofloxacin 
therapy. 
Data are part of the doctoral thesis of E. Lozo to be submitted to 
the Fachbereich Huinanniedizin, FU Berlin. Supported by a grant 
from DFG. 
lp2421 Ultrastructure of achilles tendon in rats after 
ofloxacin exposure 
M. Shakibaei, K. Pfister, K. Schwabe, R. Stahlmann. Freie 
Universifat Berlin, Znstitrrt.fnr Awatomic, Berlin, Germany 
Achilles tendon ruptures have been described after treatment with 
quinolones, but information on tendon morphology is scarce. We 
performed extensive electron microscopic studies with Achilles 
tendon specimens fi-om ofloxacin-treated rats. The anmials received 
oral doses of 1200 nig ofloxacidkg body weight once daily for 1, 3, 
5 or 10 days. Juvenile rats treated at the age of 4-5 weekt were stud- 
ied a t  3 or 6 months. Some of the animals were fed a magnesiun- 
deficient diet to answer the question if magnesium deficiency 
enhances the quinolone-induced effects. Our results can be summa- 
rized 3s follows: (1) Ofloxacin induces alterations predominantly in 
the cellular coinponents of the tendon; cells showed swollen niito- 
choiidria and enlarged endoplasmic reticulum. (2) Similar alterations 
were seen in juvenile rats (after one dose) as well as in  adult rats (after 
10 doses only); the effects were more pronounced in juvenile magne- 
sium-defcicient rats. In rats that had been treated as juveniles the 
changes were still detectable 3 or 6 months after treatment. Effects 
observed in cartilage and tendons show similar pathologic features, 
indicating that quinolone-induced arthropathy and quinolone- 
induced tendopathy might be different clinical manifestations of the 
same toxic effect on cellular components of coiinective tmue struc- 
tures. 
Data are part of the doctoral thesis of K. Pfister to be submitted 
to the Fachbereich Humanmedizin, FU Berlin. Supported by a grant 
from DFG. 
v] Grepafloxacin: a review of the safety profile in 
clinical trials and post-marketing surveillance 
E Vogel', W Elies', H. Lode3. 'Main-Taunus-Kliniken, H$hiin, 
ZStaedrisclTe KIiniken Bielefeld, 'Lnn~qenklitiik Heckrshom, Berlin, 
Germany 
Objectives: To give an overview of the safety pi-ofile of 
grepafloxacin regarding preclinical investigations, clinical trials and 
post -marketing surveillance. 
Methods: Review ofpreclinical, clinical phate I1 and 111 and post- 
marketing surveillance tolerability data of grepafloxacin. 
Results: The safety profile of grepafloxacin has already been char- 
acterized in a number of preclinical and clinical studies. A photo- 
sensitivity study demonstrated equivalence with ciprofloxacin, and a 
study in elderly individuals taking the highest clinical dose of 
grepafloxacin indicated that the prolongation of the Qtc by 
grepafloxacin was less than 2 ms: 15 times smaller than that observed 
in a study with erythromycin. Preclinical investigations have shown 
that the toxicologic profile of grepafloxacin is similar to that of other 
fluoroquinolones, and phase I studies in humans have confirmed 
these data. The most common adverse events in phase I I  and I I I  clin- 
ical studies with grepafloxacin conducted in the USA and UK in 
more than 3000 patients with respiratory tract infections were 
gastrointestinal. such as nausea, vomiting and diarrhea. The 
frequency ofthese was similar to that seen with ciprofloxacin. Recent 
data from a post-marketing surveillance study in 9398 patients 
confirm an  excellent tolerability and safety profile of grepafloxacin. 
Only 2.3% of patients reported adverse events, although many 
patients (n=7310) received concomitant medications, r.g. theo- 
phylline (n=  31 35). 
Conclusions: Grepafloxacin is a well-tolerated fluoroquinolone 
suitable for the treatment of community-acquired respiratory infec- 
tions. 
m] Effect of dosing with food and bedtime dosing 
on the incidence of dizzinessllightheadedness 
with trovafloxacin in young, healthy, female 
subjects 
J. Vincent', M. Agin', L. Laboy-Gordl', T. Hunt', J. Carlson', G. 
Apselop, 0. Kuyel. 'Pfizer Cenfral Rescarrh, Groton, C?; 'PPD 
Plmwm-o, A t d n ,  T X ,  'PRACS Farp,  ND, "Ohio Stare Universif)!, 
Columbus, OH, USA 
Background: Dizziness/lightheadednes~ (DIL) is the most coininon 
adverse event with trovafloxacin (T), especially in young women. 
Methods: A randomized, single-dose, three-period, three-treat- 
inent, double-blind, placebo-controlled, crossover, multicenter study 
was conducted in 169 healthy, young, female subjects, mean age 24.7 
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years (18-35), mean weight 61.9 kg. The three treatments, separated 
by 7-day washouts, comprised fasted, fed and bedtime dosing of 200 
mg T. During each treatment period, subjects ate a standard dinner 
at 7:00 pm.,  went to bed at 11:00 p.m. (day I), and ate a standard 
breakfast at 9:00 a.m. on day 2. Dosing with T or placebo occurred 
at 11:OO p.m. on day 1, and on day 2 at 7:00 a.m. and 9:20 a.m. (after 
breakfast). Incidence, time of onset, duration, and severity of D/L 
and other volunteered adverse events were assessed for each treat- 
ment. 
Results: No sleep disturbance was reported. Compared to the 
fasted state, the odds of experiencing D/L were decreased 2- and 4- 
fold, respectively, with food and bedtime dosing. Based on subjects 
who responded differently in each treatment pair, the number expe- 
riencing D/L was reduced by 76% (fasted versus bedtime), 49% 
(fasted versus fed), and 55% (fed versus bedtime). Independent of 
treatment, the overall incidence of D/L decreased over time. Among 
subjects receiving all three treatments, the reduction from period 1 
to period 3 was 41%. 
Conclusions: This study demonstrated that D/L associated with 
T can be significantly reduced by dosing with food or at bedtime. 
Ip245j Azithromycin: clinical safety and tolerability 
B. Barsic’, A.M. Banaszak2, M. Matrapazovski’, I .  Klina?. 
‘University Hospital of Infectious Diseases, ‘Pliva d.d., Zagreb, Croatia 
Objectives: In order to assess the tolerability of azithromycin and 
compare it to the tolerability of other antibiotics we analyzed safety 
data &om 23 comparative and 35 non-comparative clinical trials. 
Methods: The majority of adult patients received azithromycin in 
a total dose of 1.5 g given for 3 or 5 days, patients with 
urethritis/cervicitis received a single 1-g dose, patients with erythema 
migrans a total dose of 3-4.5 g, and Helicolracterpylori-positive patients 
with peptic ulcer or gastritis up to 7 g. 
Results: Side effects were recorded in 5.6% of 3576 adults and 
6.5% of 1151 children treated with azithromycin, and in 13.9% of 
936 adults and 17.6% of 408 children treated with other antibiotics 
(P=0.001). Treatment was discontinued due to side effects in 0.1% 
of adults and 0.4% of children treated with azithromycin, and in 2.6% 
of adults and 2.0% of children treated with other antibiotics 
{P=0.001). Laboratory abnormalities were observed in 7.1% ofadults 
and 4.0% of children treated with azithromycin, and in 5.8% of adults 
and 2.4% of children treated with other antibiotics (p 0.05). 
Conclusions: Presented results show that azithromycin is toler- 
ated equally or better than other antibiotics, in both adults and chil- 
dren. Side effects, mostly gastrointestinal, are mild in severity and 
very rarely require discontinuation of the treatment. The most 
common laboratory abnormalities were transient eosinophilia and 
elevation of liver enzymes. 
1p246j The pharmacokinetics and tolerability of the 
oral neuraminidase inhibitor Ro 64-0796 in 
subjects with renal impairment 
G. He, J. Massarella, R. Robson, A. Dorr, H. Tang, B. Rana, L. 
Calvert, A. Brown, I? Ward, N: Wood, M. Hale. Roche Global 
Development, USA, UK; Roche Discowry, Welwyn, UK 
Ro 64-0796/GS4104 is a highly bioavailable prodrug of Ro 64- 
0802, a potent and selective inhibitor of influenza A and B 
neurammidases. Preclinical data indicate that both compounds are 
eliminated via kidney, so renal impairment may affect the pharma- 
cokinetics of both prodrug and metabolite. We performed this study 
to determine the safety, tolerability and pharmacokinetic character- 
istics of R o  64-0796 in renally impaired subjects. Twenty subjects 
(aged 18-59) were evenly allocated to one of the four groups depend- 
ing on their renal clearance (Clcr). Each subject received a total of 
10 doses o f R o  64-0796 100 mg in a 5-day b.i.d. regimen. The study 
demonstrated that the clearance of R o  64-0796 and Ro 64-0802 
decreases as the severity of renal impairment increases. Although the 
total exposure (AUC) of the active drug was increased up to 10-fold 
in the severe renally impaired group, tolerability was not compro- 
mized. AU 48 adverse events reported were mild or moderate, and 
not related to the study drug. The incidence of adverse events was 
higher in the three renally impaired groups; however, the investiga- 
tor considers these events to be typical for the subjects’ pre-existing 
condition and not related to the study drug. There were no prema- 
ture withdrawals from the study and no apparent dose effect on vital 
signs and safety laboratory parameters. 
This study concluded that as the increased drug exposures were 
not associated with reduced tolerability, a reduction in dose or dosing 
frequency is only recommended for patients with severe renal impair- 
ment. 
lp2471 The safety and pharmacokinetics of the 
neuraminidase inhibitor Ro 64-0796 when 
administered concurrently with paracetamol 
G. He, J. Massarella, M. Aitken, A. Dorr, H. Tang, C. Critchley, 
A. Brown, l? Ward, N. Wood, M. Hale, H. Wiltshire, Rocke Global 
Development, Palo .4h, CA, U S A  
Ro 64-0796 is a prodrug of R o  64-0802, which is a potent and selec- 
tive influenza A and B neuraminidase inhibitor. Both compounds are 
mainly excreted renally. Neither in vitro nor in vivo experiments 
have demonstrated any involvement of cytochrome P450 in the 
metabolism of the prodrug or its active metabolite. As paracetamol is 
a widely used relief medication in influenza, we performed a 
randomixed cross-over study to investigate the effects of R o  64-0796 
on the safety, tolerability and pharmacokinetics of paracetamol. Six 
healthy volunteers aged 26-49 years were randomly assigned to one 
of two oral treatment sequences involving administration of a single 
dose of paracetamol 500 mg either alone or in combination with R o  
64-0796 200 mg followed by R o  64-0796 200 mg b.i.d. for 5 days. 
Dosing sequence reversed after 5 days washout. Twelve mild adverse 
events were reported and mostly occurred during the 5-day R o  64- 
0796 regimen. There were no serious adverse events, withdraws, or 
clinically significant abnormal laboratory parameters, ECG or vital 
signs. Combination therapy gave mild and non-statistically significant 
decreases in AUC (13%) and C,,, (9%) for paracetamol. When 
compared with historical control data, total exposure of R o  64-0796 
and its active metabolite remained comparable. This study demon- 
strates that there is no clinically relevant drug interaction when 
paracetamol 500 mg and R o  64-0796 200 mg are administered 
concurrently, and that the combination is we11 tolerated. 
Acute renal failure following treatment with 
antibiotics; results of a retrospective hospital- 
based study 
A. Radulescu, I.S. Bocsan, M. Glierman, S. Oltean. University .f 
Medicine and Pharmacy, Cluj-Napoca, Romania 
Objectives: To establish the rate and the clinical outcome of acute 
renal failure due to rifampin and aminoglycosides. 
Methods: During 1991-97 a retrospective study was performed 
to assess all ARF episodes encountered in the CIUJ nephrology refer- 
ral centre for adults (covering 800 000 people). ARF was defined as 
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an acute deterioration of renal function with a sudden rizc in serum 
creatniine concentration to more than 2 ing% 
Results: O f  thc 359 cases meeting case definition, the most 
frequent causes of ARF were: medical (60%) surgical (obstructive and 
postoperative, 33%). Among medical causes of ARE nephrotoxic 
agents accounted for 80 cases- 22%1:15 cases of interstitial nephritis 
due to rifampin, acute tubular necrosis due to aminoglycosides 21 
cases, following the use of radiographic media and metals 5 cases, due 
to henioglobinuria and myoglobinuria 31 cases, due to organic 
solvents 8 cases. In all cases of ARF due to rifampin, the drug was 
used i n  definitely diagnosed tuberculosis. In 13 cases ARF occurred 
abruptly within 48 h after a new antituberculous combination, 
including rifampin, in internmittent administration (dosages < 1200 
mg). Aniinoglycosides induced AKF in cases in which life-threaten- 
ing conditions, such as sepsis (6), endocarditis (1) and surglcal proce- 
dures (S), occurred. ARF was severe in all cases due to the above 
mentioned drugs demonstrated by: oliguria at adinission (urine 
output <400 mL/day in 18 cases), hematologic failure (21 with 
heinatocrit <30%), the need for dialysis (33 cases). All episodes of 
ARF due to rifampin recovered after conservative treatment or 5-12 
dialyIis (12 cases). Seven cases of ARF due to aminoglycosides were 
healed, in 2 death occurred, and in 13 cases the long-term outcome 
was not known. 
Conclusions: ARF is a rare and severe adverse effect of the 
discontinuation of rifampin therapy but it is not a cause of death, 
while the aminoglycoside nephrotoxity complicates the outcome of 
severe diseases. 
I P250 I Hepatic monooxygenase activities in juvenile 
rats after pre- and postnatal exposure to 
indinavir 
T.G. Schulz, B. Krause, K. Riecke, R. Stahlniann, E. Hallier. 
D e p r r i w ~ t  of Occupafional Health, Georg-Aigust- University Gor t inp t ,  
Gottirigen, Ckrniariy 
Background: Indinavir is an inhibitor of the HIV protease. Only 
limited data are available on the effects of indinavir on cytochronie 
P450-dependent monooxygenases, which are important enzymes of 
xenobiotic metabolism. The enzyme-modulating etfccts in the 
offspring after pre- and postnatal exposure to indinavir are completely 
unkown. 
Methods: Wistar rats were treated orally from day 9 of gestation 
until day 21 of lactation with either vehicle alone (starch solution, 
2%) or indinavir (500 nig/kg body weight once daily). From day 7 
postpartum on, 4 male and 4 female offspring of each treatment 
group were sacrificed weekly Microsonial fractions were prepared 
from liver and investigated for several monooxygenase activities such 
as niethoxy-, ethoxy-, pentoxy- and benzoyloxyresorufin O-dealky- 
lases (MROD, EROD, PROD, BROD). These enzyme activities are 
useful to detect CYP 1 A 1, CYP 1 A2, CYP2B2 and CYP3 A 1 in 
rat tissues. 
Results: EROD and MROD activities were low at postnatal day 
7 and increased during the following 6 weeks. PROD and BROD 
activities increased only moderately during postnatal development. 
However, no significant difhences were found between control and 
indinavir-treated rats for any of the enzymes investigated. 
Conclusions: These results gave no indication for an enzyme 
induction or inhibition by indinavir during the postnatal develop- 
ment with respect to CYPIA1, CYPlA2, CYP2B2 and CYP3Al 
under our experimental conditions. 
Ip251] Effects of protease inhibitors on pre- and 
postnatal development of rats 
K. Riecke, M. Shakibaei, I. Chahoud, R. Stahlmann. Irrstitiite of 
Clinical Plrarniucol~yy and %xicology, Bei@rnin Frariklin bfrdiral 
Cenfrc, Freie Unrversiriir Berlin, Germany 
Background: Indinavir and ritonavir are inhibitors of the HIV 
protease. Few data have been published on their reproductive and 
developmental toxicities. 
Methods: Teratology studies were performed on Wimr  rats 
treated orally with indmavir from day 9-1 1 of gestation (500 mg/kg 
b.i.d.) or day 6-15 (SOU nig/kg once daily) or vehicle (starch solu- 
tion 2%). At day 21, fetuses were explanted for skeletal evaluation. 
Postnatal studies were performed on rats treatcd from day 9 of gesta- 
tion until day 21 of lactation with either vehicle alone, indinavir or 
ritonavir (500 mg/kg once daily). Landmarks of postnatal develop- 
ment were monitored. From postpartal day 7 on, 10 male and 10 
female offspring of each treatment group were sacrificed weekly. 
Organ weights were taken, and tissue samples were collected for elec- 
tron microscopy 
Results: Fetuses showed several skeletal anonlalies such as addi- 
tional lumbar ribs and asymmetric ossification of vertebrae. 
Postnatally, body weight in otfspring treated with indinavir or riton- 
avir was decreased. At postnatal day 14, the indmavir-treated 
oEspring had a lower relative liver weight when compared to 
controls. In both the indindvir (7/347=2%) and in  the ritonavir 
(1 /6Y) groups, offspring with unilateral anophthalniia were observed 
at day 18. 
Conclusions: These results suggest that HIV protease inhibitors 
should be used carefully in women who are pregnant or who could 
become pregnant during the treatment (post-exposure prophylaxi?) 
until further data are available from their use in pregnancy. The sinii- 
larity of the protease inhibitor binding site to the  retinoic acid recep- 
tor adds to this concern. 
Community acquired pneumonia 
Evaluation of serologic response to Coxiella 
burnetii in patients with atypical pneumonia 
I? Karaboyia-Karafillidis, E. Vagiakou-Voudris, C .  Kakkari, A. 
Souras, D. Mylona-Petropoulou. Microbiology Laborarory, IVutiiirial 
Rubella Reference Center, Gerreral Disrrirr Huqiral ‘C. C;ewiniaras’, 
Athens, Grtwe 
Objectives: To evaluate the role of Cuxiella burrzetii in cases of atyp- 
ical pneumonia in adults at a district general hospital. 
Materials and methods: Blood samples were collected from 1 50 
patients (1 10 men, 40 women age 18-60 years old) hospitalized with 
atypical pneumonia in the General District Hospital of Athens. The 
diagnosis of atypical pneumonia was based on the clinical picture, the 
chest X-ray and the serologic study. The serologic study for Ckxiella 
burnetii was based on an indirect ininiuiiofluorescence tect. The crite- 
ria for acute infection from Coxiella burnctii were (1) phase 11 IgG titer 
=1/512, (2) phase I1 IgM =1/20 and or seroconversion. 
Results: Only 13 of the 150 patients were (8.66%) found to be 
seropositive for IgG antibodies to Coxidla burnetii at a titer of 1/31 2 
or more. IgM antibodies were detected in 9 out of the 13 patients 
with positive IgG antibodies (9/150, 6%). Seroconversion was found 
in 3 of the patients. 
